Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06983028 · ClinicalTrials.gov registry record · Phase 2
Atacicept in Multiple Glomerular Diseases
A Phase 2 study of Nephrotic Syndrome and FSGS, sponsored by Vera Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT06983028: Recruiting Phase 2 study of Nephrotic Syndrome and FSGS, sponsored by Vera Therapeutics.
NCT06983028 is a Phase 2 study of Nephrotic Syndrome and FSGS that is actively recruiting participants, run by Vera Therapeutics. The registered enrollment target is 200 participants, below the 619-participant average among 7 other Nephrotic Syndrome trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06983028, a Phase 2 study of Nephrotic Syndrome and FSGS, is actively recruiting participants, sponsored by Vera Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and tolerability of atacicept in adult and adolescent participants and to measure the effect in reducing proteinuria and preserving renal function.
Primary Outcome
Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events of special interest (AESIs), study drug discontinuation due to TEAEs
Conditions Studied
Interventions
- DRUG Atacicept
Study Locations (1)
California
- Vera Therapeutics - Brisbane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-07-07 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
What NCT06983028 shows while recruiting
NCT06983028 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 619-participant average among 7 other Nephrotic Syndrome trials with a reported enrollment target (68% lower).
The record links to 5 conditions, with Nephrotic Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Atacicept is the first listed.
NCT06983028 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06983028 about?
NCT06983028 is a clinical study titled "Atacicept in Multiple Glomerular Diseases". The purpose of this study is to evaluate the safety and tolerability of atacicept in adult and adolescent participants and to measure the effect in reducing proteinuria and preserving renal function.
What is the current status of trial NCT06983028?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-07-07. Estimated completion is 2027-11.
What conditions does trial NCT06983028 study?
This clinical trial studies the following conditions: Nephrotic Syndrome, FSGS, IgAN, MCD, pMN.
What interventions are being tested in trial NCT06983028?
The interventions under investigation include: Atacicept (DRUG).
Who is sponsoring clinical trial NCT06983028?
This trial is sponsored by Vera Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06983028 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nephrotic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Belimumab With Rituximab for Primary Membranous Nephropathy
RECRUITING · Phase 2
-
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
RECRUITING · Phase 2
-
Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
RECRUITING
-
Immune System Related Kidney Disease
RECRUITING
-
Diuretic Tuner Clinical Decision Support
RECRUITING · NA
-
Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI